Arlington, Va.—Hepatologists treating patients with cholangiopathies have had few options. But that might be changing.
Several promising agents are now in clinical trials and development for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Elizabeth J. Carey, MD, FAASLD, an associate professor of medicine at Mayo Clinic Arizona, in Scottsdale, reviewed the progress at the 2018 Emerging Trends Conference of the American Association for the Study of Liver Diseases.
